Bullfrog AI Holdings, Inc. (BFRG)
NASDAQ: BFRG · Real-Time Price · USD
0.6624
+0.0023 (0.35%)
Jun 23, 2026, 4:00 PM EDT - Market closed
Bullfrog AI Revenue
Bullfrog AI had revenue of $116.67K in the twelve months ending March 31, 2026. In the year 2025, Bullfrog AI had annual revenue of $116.67K.
Revenue (ttm)
$116.67K
Revenue Growth
n/a
P/S Ratio
105.27
Revenue / Employee
$6,863
Employees
17
Market Cap
12.28M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 116.67K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 65.00K | 55.00K | 550.00% |
| Dec 31, 2022 | 10.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Definitive Healthcare | 238.26M |
| CareCloud | 124.14M |
| OptimizeRx | 107.35M |
| DarioHealth | 21.19M |
| Healthcare Triangle | 20.04M |
| VSee Health | 14.46M |
| Mobile-health Network Solutions | 7.32M |
| OneMedNet | 1.32M |
BFRG News
- 21 days ago - BullFrog AI Announces New Commercial Leadership Team to Execute Growth Strategy for its Integrated Pharma AI Platform - GlobeNewsWire
- 25 days ago - Bullfrog AI registers to sell 2M shares of common stock for holders - TheFly
- 2 months ago - Bullfrog AI regains compliance with Nasdaq - TheFly
- 2 months ago - BullFrog AI Regains Compliance with Nasdaq Shareholders' Equity Requirement - GlobeNewsWire
- 2 months ago - BullFrog AI Announces Participation at AACR Annual Meeting - GlobeNewsWire
- 2 months ago - BullFrog AI issues shareholder letter highlighting recent progress, outlook - TheFly
- 2 months ago - BullFrog AI issues shareholder letter highlighting recent progress, outlook - TheFly
- 2 months ago - BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners - GlobeNewsWire